Advertisement

Clinical Scenario: Bladder Preservation

  • Albert J. ChangEmail author
  • Maurice Marcel Garcia
  • Mack RoachIII
Chapter

Abstract

Multi-modality bladder preservation with maximal transurethral resection of the bladder tumor (TURBT) followed by definitive chemoradiation is becoming increasingly popular and an attractive option to radical cystectomy for treatment of muscle invasive bladder cancer. Ideal candidates are patients with unifocal, T2 disease undergoing maximal TURBT with no gross residual, patients with tumors <5 cm, and patients with good bladder function. Bladder preservation treatment is well-tolerated, offers similar survival outcomes to radical cystectomy (5y OS 40–60 %), and approximately two-thirds of patients are cured 5 years after treatment. Studies have demonstrated that the majority of patients undergoing bladder preservation are satisfied with their quality of life with minimal urinary distress.

Keywords

Bladder Radiation Chemotherapy Cystectomy TURBT 

References

  1. 1.
    Efstathiou JA, Spiegel DY, Shipley WU, Heney NM, Kaufman DS, Niemierko A, et al. Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience. Eur Urol. 2012;61(4):705–11. PubMed PMID: 22101114.PubMedCrossRefGoogle Scholar
  2. 2.
    Shipley WU, Prout Jr GR, Einstein AB, Coombs LJ, Wajsman Z, Soloway MS, et al. Treatment of invasive bladder cancer by cisplatin and radiation in patients unsuited for surgery. JAMA. 1987;258(7):931–5. PubMed PMID: 3613023.PubMedCrossRefGoogle Scholar
  3. 3.
    James ND, Hussain SA, Hall E, Jenkins P, Tremlett J, Rawlings C, et al. Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. N Engl J Med. 2012;366(16):1477–88. PubMed PMID: 22512481.PubMedCrossRefGoogle Scholar
  4. 4.
    Shipley WU, Winter KA, Kaufman DS, Lee WR, Heney NM, Tester WR, et al. Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of Radiation Therapy Oncology Group 89–03. J Clin Oncol. 1998;16(11):3576–83. PubMed PMID: 9817278.PubMedGoogle Scholar
  5. 5.
    Rodel C, Grabenbauer GG, Kuhn R, Papadopoulos T, Dunst J, Meyer M, et al. Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results. J Clin Oncol. 2002;20(14):3061–71. PubMed PMID: 12118019.PubMedCrossRefGoogle Scholar
  6. 6.
    Fung CY, Shipley WU, Young RH, Griffin PP, Convery KM, Kaufman DS, et al. Prognostic factors in invasive bladder carcinoma in a prospective trial of preoperative adjuvant chemotherapy and radiotherapy. J Clin Oncol. 1991;9(9):1533–42. PubMed PMID: 1875217.PubMedGoogle Scholar
  7. 7.
    Coppin C, Gospodarowicz M. The NCI-Canada trial of concurrent cisplatin and radiotherapy for muscle invasive bladder cancer. Prog Clin Biol Res. 1990;353:75–83. PubMed PMID: 2217429.PubMedGoogle Scholar
  8. 8.
    George L, Bladou F, Bardou VJ, Gravis G, Tallet A, Alzieu C, et al. Clinical outcome in patients with locally advanced bladder carcinoma treated with conservative multimodality therapy. Urology. 2004;64(3):488–93. PubMed PMID: 15351577.PubMedCrossRefGoogle Scholar
  9. 9.
    Gospodarowicz MK, Hawkins NV, Rawlings GA, Connolly JG, Jewett MA, Thomas GM, et al. Radical radiotherapy for muscle invasive transitional cell carcinoma of the bladder: failure analysis. J Urol. 1989;142(6):1448–53. discussion 53-4, PubMed PMID: 2585617.PubMedGoogle Scholar
  10. 10.
    Shipley WU, Rose MA, Perrone TL, Mannix CM, Heney NM, Prout Jr GR. Full-dose irradiation for patients with invasive bladder carcinoma: clinical and histological factors prognostic of improved survival. J Urol. 1985;134(4):679–83. PubMed PMID: 4032570.PubMedGoogle Scholar
  11. 11.
    Hart S, Skinner EC, Meyerowitz BE, Boyd S, Lieskovsky G, Skinner DG. Quality of life after radical cystectomy for bladder cancer in patients with an ileal conduit, cutaneous or urethral kock pouch. J Urol. 1999;162(1):77–81. PubMed PMID: 10379744.PubMedCrossRefGoogle Scholar
  12. 12.
    Jenkins BJ, Caulfield MJ, Fowler CG, Badenoch DF, Tiptaft RC, Paris AM, et al. Reappraisal of the role of radical radiotherapy and salvage cystectomy in the treatment of invasive (T2/T3) bladder cancer. Br J Urol. 1988;62(4):343–6. PubMed PMID: 3191360.PubMedCrossRefGoogle Scholar
  13. 13.
    Shearer RJ, Chilvers CF, Bloom HJ, Bliss JM, Horwich A, Babiker A. Adjuvant chemotherapy in T3 carcinoma of the bladder. A prospective trial: preliminary report. Br J Urol. 1988;62(6):558–64. PubMed PMID: 3064861.PubMedCrossRefGoogle Scholar
  14. 14.
    De Neve W, Lybeert ML, Goor C, Crommelin MA, Ribot JG. Radiotherapy for T2 and T3 carcinoma of the bladder: the influence of overall treatment time. Radiother Oncol. 1995;36(3):183–8. PubMed PMID: 8532904.PubMedCrossRefGoogle Scholar
  15. 15.
    Mameghan H, Fisher R, Mameghan J, Brook S. Analysis of failure following definitive radiotherapy for invasive transitional cell carcinoma of the bladder. Int J Radiat Oncol Biol Phys. 1995;31(2):247–54. PubMed PMID: 7836076.PubMedCrossRefGoogle Scholar
  16. 16.
    Shipley WU, Zietman AL, Kaufman DS, Althausen AF, Heney NM. Invasive bladder cancer: treatment strategies using transurethral surgery, chemotherapy and radiation therapy with selection for bladder conservation. Int J Radiat Oncol Biol Phys. 1997;39(4):937–43. PubMed PMID: 9369144.PubMedCrossRefGoogle Scholar
  17. 17.
    Miller LS. Bladder cancer: superiority of preoperative irradiation and cystectomy in clinical stages B2 and C. Cancer. 1977;39(2 Suppl):973–80. PubMed PMID: 402205.PubMedCrossRefGoogle Scholar
  18. 18.
    Bloom HJ, Hendry WF, Wallace DM, Skeet RG. Treatment of T3 bladder cancer: controlled trial of pre-operative radiotherapy and radical cystectomy versus radical radiotherapy. Br J Urol. 1982;54(2):136–51. PubMed PMID: 7044462.PubMedCrossRefGoogle Scholar
  19. 19.
    Sell A, Jakobsen A, Nerstrom B, Sorensen BL, Steven K, Barlebo H. Treatment of advanced bladder cancer category T2 T3 and T4a. A randomized multicenter study of preoperative irradiation and cystectomy versus radical irradiation and early salvage cystectomy for residual tumor. DAVECA protocol 8201. Danish Vesical Cancer Group. Scand J Urol Nephrol Suppl. 1991;138:193–201. PubMed PMID: 1785004.PubMedGoogle Scholar
  20. 20.
    Svatek RS, Shariat SF, Novara G, Skinner EC, Fradet Y, Bastian PJ, et al. Discrepancy between clinical and pathological stage: external validation of the impact on prognosis in an international radical cystectomy cohort. BJU Int. 2011;107(6):898–904. PubMed PMID: 21244604.PubMedCrossRefGoogle Scholar
  21. 21.
    Nepple KG, O’Donnell MA. The optimal management of T1 high-grade bladder cancer. Can Urol Assoc J. 2009;3(6 Suppl 4):S188–92. PubMed PMID: 20019983. Pubmed Central PMCID: 2792452.PubMedCentralPubMedGoogle Scholar
  22. 22.
    Harland SJ, Kynaston H, Grigor K, Wallace DM, Beacock C, Kockelbergh R, et al. A randomized trial of radical radiotherapy for the management of pT1G3 NXM0 transitional cell carcinoma of the bladder. J Urol. 2007;178(3 Pt 1):807–13. discussion 13, PubMed PMID: 17631326.PubMedCrossRefGoogle Scholar
  23. 23.
    Weiss C, Wolze C, Engehausen DG, Ott OJ, Krause FS, Schrott KM, et al. Radiochemotherapy after transurethral resection for high-risk T1 bladder cancer: an alternative to intravesical therapy or early cystectomy? J Clin Oncol. 2006;24(15):2318–24. PubMed PMID: 16710030.PubMedCrossRefGoogle Scholar
  24. 24.
    Leissner J, Ghoneim MA, Abol-Enein H, Thuroff JW, Franzaring L, Fisch M, et al. Extended radical lymphadenectomy in patients with urothelial bladder cancer: results of a prospective multicenter study. J Urol. 2004;171(1):139–44. PubMed PMID: 14665862.PubMedCrossRefGoogle Scholar
  25. 25.
    Poulsen AL, Horn T, Steven K. Radical cystectomy: extending the limits of pelvic lymph node dissection improves survival for patients with bladder cancer confined to the bladder wall. J Urol. 1998;160(6 Pt 1):2015–9. Discussion 20, PubMed PMID: 9817313.PubMedGoogle Scholar
  26. 26.
    Harris SJ, Buchanan RB. An audit and evaluation of bladder movements during radical radiotherapy. Clin Oncol. 1998;10(4):262–4. PubMed PMID: 9764380.CrossRefGoogle Scholar
  27. 27.
    McBain CA, Logue JP. Radiation therapy for muscle-invasive bladder cancer: treatment planning and delivery in the 21st century. Semin Radiat Oncol. 2005;15(1):42–8. PubMed PMID: 15662606.PubMedCrossRefGoogle Scholar
  28. 28.
    Thariat J, Trimaud R, Angellier G, Caullery M, Amiel J, Bondiau PY, et al. Innovative image-guided CyberKnife stereotactic radiotherapy for bladder cancer. Br J Radiol. 2010;83(990):e118–21. PubMed PMID: 20505025, Pubmed Central PMCID: 3473597.PubMedCentralPubMedCrossRefGoogle Scholar
  29. 29.
    Eswara JR, Efstathiou JA, Heney NM, Paly J, Kaufman DS, McDougal WS, et al. Complications and long-term results of salvage cystectomy after failed bladder sparing therapy for muscle invasive bladder cancer. J Urol. 2012;187(2):463–8. PubMed PMID: 22177159.PubMedCrossRefGoogle Scholar
  30. 30.
    Lynch TH, Waymont B, Dunn JA, Wallace DM. Urologists’ attitudes to the management of bladder cancer. Br J Urol. 1992;70(5):522–5. PubMed PMID: 1467859.PubMedGoogle Scholar
  31. 31.
    Henningsohn L, Wijkstrom H, Dickman PW, Bergmark K, Steineck G. Distressful symptoms after radical radiotherapy for urinary bladder cancer. Radiother Oncol. 2002;62(2):215–25. PubMed PMID: 11937249.PubMedCrossRefGoogle Scholar
  32. 32.
    Efstathiou JA, Bae K, Shipley WU, Kaufman DS, Hagan MP, Heney NM, et al. Late pelvic toxicity after bladder-sparing therapy in patients with invasive bladder cancer: RTOG 89-03, 95-06, 97-06, 99-06. J Clin Oncol. 2009;27(25):4055–61. PubMed PMID: 19636019, Pubmed Central PMCID: 2734419.PubMedCentralPubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  • Albert J. Chang
    • 1
    Email author
  • Maurice Marcel Garcia
    • 2
  • Mack RoachIII
    • 1
  1. 1.Department of Radiation Oncology, Helen Diller Family Comprehensive Cancer CenterUniversity of California, San FranciscoSan FranciscoUSA
  2. 2.Department of Urology, (Moffit-Long, Mount Zion), San Francisco General Hospital and The San Francisco Veteran’s Adminstration HospitalUniversity of California San FranciscoSan FranciscoUSA

Personalised recommendations